|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
254,036,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$22.93 - $22.93 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Cross Leland H |
Senior V.P., Tech. OperationsO |
|
2006-09-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
310,932 |
|
- |
|
Herendeen Paul |
Exec. V.P. and CFOOfficer |
|
2006-09-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
851,542 |
|
- |
|
Reichel W Carl |
President, PharmaceuticalsOffi |
|
2006-09-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
171,636 |
|
- |
|
Reichel W Carl |
President, PharmaceuticalsOffi |
|
2006-09-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
830,100 |
|
- |
|
Bruno Anthony D |
Exec. V.P., Corp. DevelopmentO |
|
2006-09-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
171,636 |
|
- |
|
Bruno Anthony D |
Exec. V.P., Corp. DevelopmentO |
|
2006-09-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
756,688 |
|
- |
|
Credit Suisse First Boston |
10% Owner |
|
2006-09-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
38,045,401 |
|
- |
|
Murray Stephen P |
Director |
|
2006-09-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
38,045,404 |
|
- |
|
Thomas H Lee Alternative Fund V Lp |
10% Owner |
|
2006-09-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
29,291,109 |
|
- |
|
Pagliuca Stephen G |
Director |
|
2006-09-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
38,045,413 |
|
- |
|
Connaughton John |
Director |
|
2006-09-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
38,045,413 |
|
- |
|
King John A |
Director |
|
2006-09-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,354,046 |
|
- |
|
Jp Morgan Partners Global Investors Selldown Cayma |
10% Owner |
|
2006-09-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
76,090,808 |
|
- |
|
Bain Capital Investors Llc |
10% Owner |
|
2006-09-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
38,045,413 |
|
- |
|
Boissonneault Roger M |
CEO & President |
|
2006-09-21 |
4 |
D |
$15.00 |
$2,436,915 |
D/D |
(162,461) |
2,022,788 |
|
- |
|
Boissonneault Roger M |
CEO & President |
|
2006-09-21 |
4 |
A |
$0.00 |
$0 |
D/D |
357,057 |
2,185,249 |
|
- |
|
Bruno Anthony D |
Exec. V.P., Corp. Development |
|
2006-09-21 |
4 |
D |
$15.00 |
$1,218,450 |
D/D |
(81,230) |
756,688 |
|
- |
|
Bruno Anthony D |
Exec. V.P., Corp. Development |
|
2006-09-21 |
4 |
A |
$0.00 |
$0 |
D/D |
178,527 |
837,918 |
|
- |
|
Cross Leland H |
Senior V.P., Tech. Operations |
|
2006-09-21 |
4 |
A |
$0.00 |
$0 |
D/D |
12,600 |
323,532 |
|
- |
|
Ellman Herman |
Senior V.P., Clinical Devel. |
|
2006-09-21 |
4 |
A |
$0.00 |
$0 |
D/D |
12,600 |
235,342 |
|
- |
|
Hara Izumi |
Sr. VP, Gen. Counsel & Sec. |
|
2006-09-21 |
4 |
A |
$0.00 |
$0 |
D/D |
15,300 |
232,822 |
|
- |
|
Herendeen Paul |
Exec. V.P. and CFO |
|
2006-09-21 |
4 |
D |
$15.00 |
$1,218,450 |
D/D |
(81,230) |
851,542 |
|
- |
|
Herendeen Paul |
Exec. V.P. and CFO |
|
2006-09-21 |
4 |
A |
$0.00 |
$0 |
D/D |
178,527 |
932,772 |
|
- |
|
Howard Alvin D |
Sr. V.P., Regulatory Affairs |
|
2006-09-21 |
4 |
A |
$0.00 |
$0 |
D/D |
15,300 |
195,134 |
|
- |
|
Reichel W Carl |
President, Pharmaceuticals |
|
2006-09-21 |
4 |
D |
$15.00 |
$1,218,450 |
D/D |
(81,230) |
830,100 |
|
- |
|
380 Records found
|
|
Page 15 of 16 |
|
|